This white paper explores the changes, challenges, and opportunities in the reimbursement environment of the G-5 countries of the European Union . Specific processes for reimbursement and pricing are outlined, as well as the approach for determining “additional medical benefit” for premium pricing. Read more. (Source: eyeforpharma, 2013).
You are here: / Show Me The evidence: How European Payers are Re-prioritising for the Future